• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • eFFECTOR and QBI to study anti-viral agent for Covid-19 treatment pharmaceutical-technology
    May 06, 2021
    eFFECTOR Therapeutics and Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), have announced a $5m cooperative agreement for a planned Phase Ib study of zotatifin (eFT226), an anti-viral agent for Covid-19 ...
  • Pfizer signs oncology agreement with STR-focused eFFECTOR pharmaceutical-technology
    January 14, 2020
    San Diego-based eFFECTOR has signed an exclusive worldwide license and collaboration agreement with Pfizer in the oncology field. The collaboration focuses on the development of small molecule inhibitors of eukaryotic initiation factor 4E (elF4E) ...
  • eFFECTOR Therapeutics completes $38.6 million Series C financing biospectrumasia
    August 11, 2017
    Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Event Data Sharing Notice
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service